Dabigatrann.达比加群
Clopidogreln.氯吡格雷
Ticagrelorn.替格瑞洛
Warfarinn.华法林
华法林
Inthismulticentertrial,patientswithatrialfibrillationwhohadundergonepercutaneouscoronaryintervention(PCI)wererandomlyassignedtotripletherapywithwarfarinplusaP2Y12inhibitor(clopidogrelorticagrelor)andaspirin(for1to3months)ordualtherapywithdabigatran(mgormgtwicedaily)plusaP2Y12inhibitorandnoaspirin.Theincidenceoftheprimaryendpointofmajororclinicallyrelevantnonmajorbleedingofeventduringfollow-upwas15.4%inthemgdualtherapygroupas
